Company newsCompany release

Beam Therapeutics BEAM

Risto-cel meets primary endpoint of at least 12 months free of severe VOCs

Beam Therapeutics also said the study met all secondary endpoints and expects to submit a U.S. biologics license application as early as year-end 2026.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Beam Therapeutics said on November 10, 2026, that topline results from its BEACON Phase 1/2 study of risto-cel in patients with sickle cell disease and severe vaso-occlusive crises were positive. The study achieved its primary efficacy endpoint of freedom from severe vaso-occlusive crises for at least 12 consecutive months, based on independently adjudicated results, and met all primary safety endpoints at a prespecified interim analysis.

Key facts

Trial
BEACON Phase 1/2 study
Drug
Risto-cel (ristoglogene autogetemcel)
Primary efficacy endpoint
Freedom from severe vaso-occlusive crises for at least 12 consecutive months
Planned U.S. BLA submission
As early as year-end 2026

All BEAM news

Source: The company's release on GlobeNewswire, November 10, 2026.

Written by GetSignal with AI from the company's press release. How we make news

Not investment advice.

More company news

The newest

All company news